CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Justin Klee

Co-Chief Executive Officer, Co-Founder and Director, Amylyx Pharmaceuticals, Inc.

Search every verified Justin Klee interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Justin Klee, co-founder and co-CEO of Amylyx Pharmaceuticals, has been active in public discussions about the company's work in neurodegenerative diseases, particularly ALS. In a June 2024 podcast, he discussed the outcomes of Amylyx's clinical trials, including the CENTAUR trial, which he said showed a slowing of disease progression and a survival benefit in ALS, and reflected on the broader state of neurodegenerative disease research, comparing it to the field of oncology 20 to 25 years ago. He also spoke about the challenges of measuring treatment effects over short time scales in these diseases. Klee has also participated in events focused on brain health and research policy. At a September 2023 event held alongside the 78th United Nations General Assembly, he emphasized the importance of bringing together diverse stakeholders to address brain health challenges and highlighted the need for innovation in diagnosis and treatment, noting limitations such as the inability to biopsy brain tissue. He also mentioned Amylyx's involvement in launching the EU ALS Coalition, a group aimed at developing policy recommendations for ALS care and treatment across the European Union. In earlier appearances, including a 2021 conversation at Brown University, he described the origins of Amylyx and the development of its lead compound, which he said was selected for its potential to target neuronal cell death.

Recent appearances

  • The Road Ahead for Former ALS Hopeful Relyvrio ft. Amylyx's Joshua Cohen and Justin Klee

    June 19, 2024 · 📺 Xtalks

    In this episode, Ayesha spoke with Joshua Cohen and Justin Klee, co-CEOs and co-founders of Amylyx Pharmaceuticals, a company developing therapeutics for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). Josh and Justin co-founded Amylyx Pharmaceuticals in 2013. Josh co-invented the oral, fixed-dose combination AMX0035 (known commercially as Albrioza in Canada and Relyvrio in the US), which is being explored for the potential treatment of neurodegenerative diseases. With a background in biomedical engineering, Josh is passionate about improving outcomes where there is a sig…

    Watch on YouTube ↗

  • Brain Health & Research at UNGA78 | Justin Klee & Josh Cohen, Amylyx

    November 30, 2023 · 📺 European Brain Council

    As part of the European Brain Council (EBC)’s Global Partnerships in Brain Research activities, EBC, in collaboration with the Baker Institute for Public Policy, the Brain Capital Alliance, and the Brain Health Nexus organised an event last September 2023 at the Science Summit at the 78th United Nations General Assembly (UNGA78). Across the globe, society is facing brain challenges like never before—improving the health and well-being of citizens has become the top priority for many governments and brain health should not be left behind. Brain disorders, neurological and mental alike, are per…

    Watch on YouTube ↗

  • 2023 WMIF | The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs

    June 12, 2023 · 📺 World Medical Innovation Forum

    The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs Drugs that target the brain are among the most challenging to develop, yet they also signify an area of extraordinary unmet need. Driven by a deeper understanding of the complex biology of the human brain and the emergence of validated molecular targets for neuropsychiatric and neurodegenerative diseases, the field is beginning to make important strides. This panel will discuss the innovative drugs for conditions such as ALS, Alzheimer’s disease, schizophrenia, and depression that are now in and/or emerging from the drug…

    Watch on YouTube ↗

  • Carney Conversations: From a Brown dorm room to a potential treatment for neurodegenerative diseases

    May 05, 2021 · 📺 Brown University

    Join the Carney Institute for Brain Science for a conversation with Brown University alumni Josh Cohen and Justin Klee about their journey from a dorm room to the development of a potential treatment for neurodegenerative diseases, such as Alzheimer’s and ALS. Cohen and Klee are the founders of Amylyx, a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for neurodegenerative disorders. This conversation was moderated by Diane Lipscombe, Reliance Dhirubhai Ambani Director of the Carney Institute, and Christopher Moore, associate director of the Carney Instit…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →